[1] Seners P, Turc G, Oppenheim C, et al. Incidence, causes and predictors of neurological deterioration occurring within 24 hours following acute ischaemic stroke: a systematic review with pathophysiological implications[J]. J Neurol Neurosurg Psychiatry, 2015, 86(1):87-94.
[2] Liu X, Zhang Z, Ruan J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores[J]. Nature,2016, 535(7610):153-158.
[3] Sun P, Yin JB, Liu LH, et al. Protective role of dihydromyricetin in Alzheimer’s disease rat model associated with activating AMPK/SIRT1 signaling pathway[J]. Biosci Rep, 2019, 39(1): BSR20180902.
[4] Semcheddine F, Guissi NEI, Liu XY, et al. Effects of the preparation method on the formation of true nimodipine SBE-β-CD/HP-β-CD inclusion complexes and their dissolution rates enhancement[J]. AAPS Pharm Sci Tech, 2015, 16(3):704-715.
[5] Wang J, Jiang C, Li X, et al. The protective mechanism of progesterone on blood-brain barrier in cerebral ischemia in rats[J]. Brain Res Bull, 2009, 79(6):426-430.
[6] Poh L, Kang SW, Baik SH, et al. Evidence that NLRC4 inflammasome mediates apoptotic and pyroptotic microglial death following ischemic stroke[J]. Brain Behav Immun, 2019, 75:34-47.
[7] Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS[J]. Nat Rev Neurosci, 2014, 15(2):84-97.
[8] Fann DYW, Lee SY, Manzanero S, et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke[J]. Cell Death Dis,2013, 4(9):e790.
[9] Diaz-Ca?estro C, Reiner MF, Bonetti NR, et al. AP-1 (activated protein-1) transcription factor Jun D regulates ischemia/reperfusion brain damage via IL-1β (interleukin-1β) [J]. Stroke, 2019, 50(2):469-477.
[10] Shen Y, Lindemeyer AK, Gonzalez C, et al. Dihydromyricetin as a novel anti-alcohol intoxication medication[J]. J Neurosci, 2012, 32(1):390-401.
[11] Hu Q, Zhang T, Yi L, et al. Dihydromyricetin inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells[J]. Biofactors, 2018, 44(2):123-136.
[12] Feng J, Wang JX, Du YH, et al. Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice [J]. CNS Neurosci Ther,2018, 24(12):1207-1218.
[13] Wang YC, Liu QX, Zheng Q, et al. Dihydromyricetin alleviates sepsis-induced acute lung injury through inhibiting NLRP3 inflammasome-dependent pyroptosis in mice model[J]. Inflammation, 2019, 42(4):1301-1310.
[14] Wu YJ, Chen ChH. Progress of adjuvant treatment with tissue plasminogen activator beyond time window in ischemic stroke[J].Acta Anatomica Sinica, 2019, 50(6):850-856. (in Chinese)
吴冶君, 陈春花. 缺血性脑卒中治疗时间窗后辅助溶栓治疗的进展[J]. 解剖学报, 2019, 50(6):850-856.
|